Cervical spondylosis is a degenerative condition that primarily causes neck pain and stiffness. It can affect one or more vertebrae in the neck. Usually, over time, the cushion between the spine's vertebrae wears out, and bones may start to rub against each other. Treatment options for cervical spondylosis include medication, physical therapy, injection therapy, and surgical procedures. Minimally invasive surgeries like decompression and arthrodesis are preferred over open surgery as they are less painful, cause minimal tissue damage, blood loss and reduced hospital stay.
The global Cervical Spondylosis Treatment Market is estimated to be valued at US$ 3.2 billion in 2023 and is expected to exhibit a CAGR of 3.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving the growth of the cervical spondylosis treatment market is the rising adoption of minimally invasive surgical procedures. Minimally invasive techniques allow surgeons to access the spine through small incisions instead of large open incisions. These procedures reduce muscle damage, blood loss, hospitalization time, and promote quicker recovery. Growing preference amongst patients and physicians for less invasive options coupled with benefits such as lower risk of surgical site infections and reduced postoperative pain are accelerating the demand for minimally invasive techniques. Development of advanced technology-based tools has made minimally invasive spine surgery safer and more effective process fuelling the market growth.
Segment Analysis
Cervical spondylosis treatment market is segmented into medication, surgery and physical therapy. The medication segment currently dominates the market due to non-invasive nature and minimal risks involved. Oral medication like NSAIDs is prescribed initially to manage pain and inflammation.
Key Takeaways
The global Cervical Spondylosis Treatment Market Demand is expected to witness high growth. The global cervical spondylosis treatment market is estimated to be valued at US$ 3.2 billion in 2023 and is expected to exhibit a CAGR of 3.5% over the forecast period 2023 to 2030.
Regional analysis related content comprises The North America region currently accounts for the largest share in the cervical spondylosis treatment market due to high prevalence of cervical spondylosis in the region and availability of advanced treatment facilities.
Key players related content comprises Key players operating in the cervical spondylosis treatment market are Pfizer, Johnson & Johnson, Bayer, Novartis, GlaxoSmithKline, Mylan, Aurobindo Pharma, Lupin, and Cadila Pharmaceuticals.
Explore more related article on this topic: https://www.ukwebwire.com/cervical-spondylosis-treatment-market-driven-by-increasing-aging-population/
Comments
0 comment